Biogen (BIIB)
(Real Time Quote from BATS)
$144.97 USD
+0.10 (0.07%)
Updated Sep 18, 2025 12:54 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIIB 144.97 +0.10(0.07%)
Will BIIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Biogen Gets EU Nod for First Postpartum Depression Drug
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
Other News for BIIB
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M
December 19th Options Now Available For Biogen (BIIB)
M&A News: Biotech Biogen Buys Alcyone Therapeutics for $85M to Boost Brain Treatments
Biogen to buy Massachusetts-based Alcyone Therapeutics